Tjip S van der Werf
Overview
Explore the profile of Tjip S van der Werf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
214
Citations
3823
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Gafar F, Ochi T, Vant Boveneind-Vrubleuskaya N, Akkerman O, Erkens C, van den Hof S, et al.
Eur Respir J
. 2020 May;
56(4).
PMID: 32471938
Background: Tuberculosis (TB) in children and adolescents is a sentinel event for ongoing transmission. In the Netherlands, epidemiological characteristics of childhood and adolescent TB have not been fully evaluated. Therefore,...
22.
van den Elsen S, Akkerman O, Wessels M, Jongedijk E, Ghimire S, van der Werf T, et al.
Eur Respir J
. 2020 May;
56(4).
PMID: 32398308
No abstract available.
23.
Groschel M, Meehan C, Barilar I, Diricks M, Gonzaga A, Steglich M, et al.
Nat Commun
. 2020 Apr;
11(1):2044.
PMID: 32341346
Recent studies portend a rising global spread and adaptation of human- or healthcare-associated pathogens. Here, we analyse an international collection of the emerging, multidrug-resistant, opportunistic pathogen Stenotrophomonas maltophilia from 22...
24.
Done M, Akkerman O, Al-Kailany W, de Lange W, de Jonge G, Kleinnijenhuis J, et al.
Infection
. 2020 Apr;
48(4):641-645.
PMID: 32333368
Background: Paradoxical reaction after the initiation of tuberculosis treatment is defined as increased inflammation following effective antimycobacterial treatment. This is a phenomenon that can severely complicate a patient's recovery, potentially...
25.
van der Werf T, Barogui Y, Converse P, Phillips R, Stienstra Y
Expert Rev Clin Pharmacol
. 2020 Apr;
13(4):391-401.
PMID: 32310683
Introduction: Pharmacological treatment of Buruli ulcer ( infection; BU) is highly effective, as shown in two randomized trials in Africa. Areas Covered: We review BU drug treatment - in vitro,...
26.
Phillips R, Robert J, Abass K, Thompson W, Sarfo F, Wilson T, et al.
Lancet
. 2020 Mar;
395(10232):1259-1267.
PMID: 32171422
Background: Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulcerans infection that damages the skin and subcutis. It is most prevalent in western and central Africa and Australia....
27.
van den Elsen S, Akkerman O, Jongedijk E, Wessels M, Ghimire S, van der Werf T, et al.
Eur Respir J
. 2020 Jan;
55(5).
PMID: 31980497
No abstract available.
28.
Martson A, Bakker M, Blokzijl H, Verschuuren E, Berger S, Span L, et al.
BMJ Open
. 2020 Jan;
10(1):e034940.
PMID: 31915177
Objectives: Infections remain a threat for solid organ and stem cell transplant recipients. Antimicrobial prophylaxis and pre-emptive therapy have improved survival of these patients; however, the failure rates of prophylaxis...
29.
Purba A, Ascobat P, Muchtar A, Wulandari L, Rosyid A, Purwono P, et al.
Infect Drug Resist
. 2019 Dec;
12:3663-3675.
PMID: 31819549
Objectives: To evaluate the clinical and microbiological appearance among hospitalized pneumonia patients focusing on resistance and risk factors for mortality in a referral hospital. Patients And Methods: The study was...
30.
Omansen T, Erbowor-Becksen A, Yotsu R, van der Werf T, Tiendrebeogo A, Grout L, et al.
Emerg Infect Dis
. 2019 Nov;
25(12):2183-2190.
PMID: 31742506
Buruli ulcer is a neglected tropical disease caused by Myocobacterium ulcerans; it manifests as a skin lesion, nodule, or ulcer that can be extensive and disabling. To assess the global...